MSLE NASDAQ
Satellos Bioscience Inc.
1W: -2.3%
1M: -6.1%
3M: +2.8%
YTD: +20.1%
$8.50
+0.00 (+0.00%)
Weekly Expected Move ±7.4%
$7
$8
$8
$9
$10
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$11.0M
52W Range5.304-13.395
Volume27,669
Avg Volume52,626
Beta1.17
Dividend—
Analyst Ratings
Company Info
CEOFrancis Gleeson
Employees18
SectorHealthcare
IndustryBiotechnology
IPO Date2012-08-03
Websitesatellos.com
Royal Bank Plaza
Toronto, ON M5J 2J1
CA
Toronto, ON M5J 2J1
CA
1 647 660 1780
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Latest News
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
Recent Insider Trades
No insider trades found